NCT06770855View on ClinicalTrials.gov

Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)

NANot yet recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 11, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
Renal Cell Carcinoma
Interventions
PROCEDURE

Total consolidative MPDT

After stopping systemic anti-cancer therapy for metastatic RCC, participant will receive one or more of the following: surgery (e.g. nephrectomy, metastasectomy, lymph node dissection), percutaneous cryoablation and/or radiotherapy (SAbR or other definitive radiotherapy).

Trial Locations (1)

19104

Abramson Cancer Center at University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT06770855 - Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC) | Biotech Hunter | Biotech Hunter